Australia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
22.85+0.19 (+0.84%)
As of 01:48PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.36B
Enterprise value 1.99B
Trailing P/E 24.13
Forward P/E 147.06
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.25
Price/book (mrq)4.65
Enterprise value/revenue 4.12
Enterprise value/EBITDA 18.12

Trading information

Stock price history

Beta (5Y monthly) 0.48
52-week change 30.89%
S&P500 52-week change 321.23%
52-week high 334.28
52-week low 320.87
50-day moving average 323.86
200-day moving average 326.56

Share statistics

Avg vol (3-month) 31.21M
Avg vol (10-day) 3771.35k
Shares outstanding 5103.84M
Implied shares outstanding 6103.84M
Float 884.83M
% held by insiders 111.41%
% held by institutions 184.19%
Shares short (28 Mar 2024) 421.33M
Short ratio (28 Mar 2024) 423.77
Short % of float (28 Mar 2024) 433.11%
Short % of shares outstanding (28 Mar 2024) 420.61%
Shares short (prior month 29 Feb 2024) 419.86M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 22.00%
Operating margin (ttm)23.39%

Management effectiveness

Return on assets (ttm)11.13%
Return on equity (ttm)21.05%

Income statement

Revenue (ttm)482.38M
Revenue per share (ttm)4.66
Quarterly revenue growth (yoy)31.40%
Gross profit (ttm)N/A
EBITDA 108.32M
Net income avi to common (ttm)105.5M
Diluted EPS (ttm)0.94
Quarterly earnings growth (yoy)88.90%

Balance sheet

Total cash (mrq)368.22M
Total cash per share (mrq)3.56
Total debt (mrq)151k
Total debt/equity (mrq)0.03%
Current ratio (mrq)4.39
Book value per share (mrq)4.90

Cash flow statement

Operating cash flow (ttm)127.04M
Levered free cash flow (ttm)128.39M